27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE:BMY) reporting forecast-beating earnings.
Intec Pharma Ltd (NASDAQ:NTEC) and Marinus Pharmaceuticals Inc (NASDAQ:MRNS) lost much of their market value this week on clinical trial setbacks.
The following are some of the key biotech catalysts in the upcoming week:
Conferences
- 2nd Annual Biotechnology Congress: July 29-30 in Chicago.
- 8th International Conference on Stroke and Cerebrovascular Diseases: July 29-30 in Stockholm, Sweden.
- 27th International Congress on Cardiology and Medical Interventions: July 31-Aug. 1 in Chicago.
Clinical Trial Readouts (mid-2019 releases)
- Immunic Inc (NASDAQ:IMUX): interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis.
- Conatus Pharmaceuticals Inc (NASDAQ:CNAT): 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis.
- Alkermes Plc (NASDAQ:ALKS): Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis.
- IMMUTEP LTD/S ADR (NASDAQ:IMMP): initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer.
- Aevi Genomic Medicine Inc (NASDAQ:GNMX): Phase 1b data for AEVI-002 in pediatric onset Crohn's disease.
- Tricida Inc (NASDAQ:TCDA): 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease.
- Curis, Inc. (NASDAQ:CRIS): Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma.
- Ultragenyx Pharmaceutical Inc (NASDAQ:RARE): Phase 1/2 data from a second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 and Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase.
- Allakos Inc (NASDAQ:ALLK): Phase 2 top-line data for AK002 in eosinophilic gastritis.
- Leap Therapeutics Inc (NASDAQ:LPTXV): Phase 1/2 data for DKN-01 plus Keytruda in esophagogastric adenocarcinoma.
- Cidara Therapeutics Inc (NASDAQ:CDTX): Phase 2 data for rezafungin in candidemia.
- Akcea Therapeutics Inc (NASDAQ:AKCA): Phase 3 data for volanesorsen in familial partial lipodystrophy.
- Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) and Zai Lab Ltd (NASDAQ:ZLAB): Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors
- ZEALAND PHARMA/S ADR (NASDAQ:ZEAL): Phase 1b data for dasiglucagon in obesity/diabetes.
- Aclaris Therapeutics Inc (NASDAQ:ACRS): Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis.
- AnaptysBio Inc (NASDAQ:ANAB): Phase 2 data for ANB019 in generalized pustular psoriasis.
- Spark Therapeutics Inc (NASDAQ:ONCE): additional Phase 1/2 data for SPK-8011 in hemophilia A
Earnings
Monday, July 29
- Medpace Holdings Inc (NASDAQ:MEDP) (before the market open)
- Alimera Sciences Inc (NASDAQ:ALIM) (after the market close)
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) (after the market close)
- Silk Road Medical Inc (NASDAQ:SILK) (after the market close)
Tuesday, July 30
- Eli Lilly And Co (NYSE:LLY) (before the market open)
- Iradimed Corp (NASDAQ:IRMD) (before the market open)
- Blueprint Medicines Corp (NASDAQ:BPMC) (before the market open)
- Meridian Bioscience, Inc. (NASDAQ:VIVO) (before the market open)
- Merck & Co., Inc. (NYSE:MRK) (before the market open)
- Incyte Corporation (NASDAQ:INCY) (before the market open)
- Infinity Pharmaceuticals Inc. (NASDAQ:INFI) (before the market open)
- NeoGenomics, Inc. (NASDAQ:NEO) (before the market open)
- Pfizer Inc. (NYSE:PFE) (before the market open)
- Amgen, Inc. (NASDAQ:AMGN) (after the market close)
- AtriCure Inc. (NASDAQ:ATRC) (after the market close)
- EXACT Sciences Corporation (NASDAQ:EXAS) (after the market close)
- T2 Biosystems Inc (NASDAQ:TTOO) (after the market close)
- BioTelemetry Inc (NASDAQ:BEAT) (after the market close)
- Gilead Sciences, Inc. (NASDAQ:GILD) (after the market close)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) (after the market close)
- Veracyte Inc (NASDAQ:VCYT) (after the market close)
Wednesday, July 31
- Amarin Corporation plc (NASDAQ:AMRN) (before the market open)
- Strongbridge Biopharma plc (NASDAQ:SBBP) (before the market open)
- United Therapeutics Corporation (NASDAQ:UTHR) (before the market open)
- Nuvectra Corp (NASDAQ:NVTR) (after the market close)
- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (after the market close)
- Exelixis, Inc. (NASDAQ:EXEL) (after the market close)
- DexCom, Inc. (NASDAQ:DXCM) (after the market close)
- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) (after the market close)
- MacroGenics Inc (NASDAQ:MGNX) (after the market close)
- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (after the market close)
- SurModics, Inc. (NASDAQ:SRDX) (after the market close)
Thursday, Aug. 1
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (before the market open)
- Akorn, Inc. (NASDAQ:AKRX) (before the market open)
- ABIOMED, Inc. (NASDAQ:ABMD) (before the market open)
- Agios Pharmaceuticals Inc (NASDAQ:AGIO) (before the market open)
- Clovis Oncology Inc (NASDAQ:CLVS) (before the market open)
- Concert Pharmaceuticals Inc (NASDAQ:CNCE) (before the market open)
- Syros Pharmaceuticals Inc (NASDAQ:SYRS) (before the market open)
- Insmed Incorporated (NASDAQ:INSM) (before the market open)
- Intellia Therapeutics Inc (NASDAQ:NTLA) (before the market open)
- Genomic Health, Inc. (NASDAQ:GHDX) (after the market close)
- Acorda Therapeutics Inc (NASDAQ:ACOR) (after the market close)
- Emergent Biosolutions Inc (NYSE:EBS) (after the market close)
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (after the market close)
- Coherus Biosciences Inc (NASDAQ:CHRS) (after the market close)
- Kindred Biosciences Inc (NASDAQ:KIN) (after the market close)
- Bio-Rad Laboratories, Inc. (NYSE:BIO) (after the market close)
- Geron Corporation (NASDAQ:GERN) (after the market close)
- Corvus Pharmaceuticals Inc (NASDAQ:CRVS) (after the market close)
- CareDx Inc (NASDAQ:CDNA) (after the market close)
- Globus Medical Inc (NYSE:GMED) (after the market close)
- Verastem Inc (NASDAQ:VSTM) (after the market close)
- Ultragenyx (after the market close)
- Kura Oncology Inc (NASDAQ:KURA) (after the market close)
Friday, Aug. 2
- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) (before the market open)
IPO
Rapt Therapeutics, a biotech company developing therapies for inflammatory diseases and cancer, is set to offer 5 million shares at an estimated price range of $14-$16. The company proposes to list its shares on the Nasdaq under the ticker symbol "RAPT."
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!